Hamlet Biopharma wins US patent, nears Japan grant for HAMLET drug technology

• Hamlet Biopharma announced a newly granted US patent, plus an impending grant in Japan, covering its HAMLET-family cancer drug candidates.
• The US cancer patent targets production methods for Alpha1H, aimed at enabling larger-scale manufacturing.
• A separate allowance covers IL-1-related technology for bladder pain syndrome, supporting development of new treatments using anakinra off-label.
• The company reported more than 150 active patents, plus over 30 pending patent applications, across multiple countries.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hamlet Biopharma AB published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.